NewStem Ltd.

NewStem is a biopharmaceutical company focused on Human Pluripotent Stem Cells (HPSCs) in general and Human Haploid Pluripotent Stem Cells (HHPSCs) in particular. These cells have the potential to change the face of medical research as they hold a pivotal role in regenerative medicine, disease therapy and cancer research. NewStem possesses pioneering intellectual property, reagents and experience related to the isolation and differentiation of HPSCs, their genetic manipulation, immunogenicity, tumorigenicity and their unique capacity in disease modeling. With this innovative research, and specialized drug and gene screening capabilities. NewStem is currently the only company worldwide to develop products based on this paradigm changing proprietary tech-nology, licensed from Yissum, Hebrew University’s technology transfer company, based on the findings and in-ventions of Prof. Nissim Benvenisty, of the Azrieli Center for Stem Cells and Genetic Research, The Hebrew University of Jerusalem.